论文部分内容阅读
有严重先兆子病病史的妇女，其止血功能异常的发生率增高，近来在小样本无对照研究的文献中已有报道，本文作者通过大样本的对照研究以了解有严重先兆子痛病史的妇女其止血功能异常的发生率。作者并对345例患有严重先兆子病病史的妇女，至少在产后Ic周测定激活蛋白C、相关的V因子变异、脱氨酸过多血症及抗心磷脂抗体。67例对照组为无妊娠并发症病史的妇女组成，血标本采集在月经后半期。患者与对照组均未口服避孕药物。结果：研究组中激活蛋白C阻抗的发生率为11．3％（32／284）与对照组的l．5％（V67）有显著差异（P一O．025）．28周前分娩的患者其发生率为18O％（9／5O）几乎为28周后分娩者（9．8％、23／234）的2倍。V因子变异的发生率为6％（17／284），仅为激活蛋白C阻抗发生率的一半，与对照组的1．5％（l／67）无差异。跳氨酸过多血症的发生率为12．l％（35／289）与对照组的小5％（3／67）无显著差异（P一O．115），但28周前分娩者中的发生率为19．O％（11／58）显著高于对照组的4．5％（Pwto．05）。抗心磷脂抗体的发生率为20．9％（6V321）显著高于对照组的7．5％（5／67）P一0．O6，28周前后分娩者的发生率分别为274％（17／62）与19．3％（SO／259）均显著高于对照组的7．5％（P＜0．O05）?
Women with a history of severe preeclampsia have an increased prevalence of hemostatic abnormalities and have recently been reported in the literature of small control-free studies. The authors of this study examined women with a history of severe pre-eclampsia through a large sample of controlled studies The incidence of abnormal hemostatic function. In addition, 345 women with a history of severe preeclampsia were tested for activin C, associated V-factor variants, hyperkalemia, and anticardiolipin antibodies at least on postnatal week 1c. Sixty-seven patients in the control group were women with no history of pregnancy complications. Blood samples were taken during the second half of menstruation. Patients and control group were not oral contraceptives. RESULTS: The incidence of activin C resistance in the study group was 11.3% (32/284) compared with 1% in the control group. 5% (V67) were significantly different (P-O.025). The rate of patients who delivered at 28 weeks was 18% (9/50), nearly doubling the number of deliveries (9.8%, 23/234) after 28 weeks. The incidence of V-factor mutation was 6% (17/284), which was only half of the activation protein C resistance and no difference from 1.5% (l / 67) of the control group. The incidence of polyamino acid is 12. There was no significant difference (P = O.115) between 1% (35/289) and 5% (3/67) of the control group, but the incidence among deliveries was 28 weeks before. O% (11/58) was significantly higher than 4.5% of the control group (Pwto.05). The incidence of anticardiolipin antibodies was 20.9% (6V321) which was significantly higher than 7.5% (5/67) P-0 in the control group. O6, the incidence of delivery before and after 28 weeks was 274% (17/62) and 19.3% (SO / 259) were significantly higher than the control group 7.5% (P <0.O05)?